Search
Cocamidopropyl betaine
go.drugbank.com/drugs/DB11350ApprovedImpurities formed during the manufacturing process are thought to increase the prevalence of contact sensitization and mild skin irritations.
Products: Balmers Hanryeoncho WQuaternium-15
go.drugbank.com/drugs/DB14198ApprovedSensitivity to Quaternium-15 may be identified with a clinical patch test.
Clonidine
go.drugbank.com/drugs/DB00575ApprovedInvestigationalClonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD. Clonidine was granted FDA approval on 3 September 1974.
Sitamaquine
go.drugbank.com/drugs/DB04909InvestigationalSitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential
R673
go.drugbank.com/drugs/DB05466Experimentalof limbic system with respect to anxiety and depression. … The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning
AGS-005
go.drugbank.com/drugs/DB05741ExperimentalAGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's
GO-203-2C
go.drugbank.com/drugs/DB15008InvestigationalGO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
GPI-1485
go.drugbank.com/drugs/DB05814InvestigationalGPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. … In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.
INM004
go.drugbank.com/drugs/DB17791InvestigationalINM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic
IMM101
go.drugbank.com/drugs/DB15851ExperimentalStudies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039].